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Original Investigation | Cardiology
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events
With Warfarin Use vs Non–vitamin K Antagonist Oral Anticoagulant Use
in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage
Chuan-Tsai Tsai, MD; Jo-Nan Liao, MD; Chern-En Chiang, MD; Yenn-Jiang Lin, MD; Shih-Lin Chang, MD; Li-Wei Lo, MD; Yu-Feng Hu, MD; Ta-Chuan Tuan, MD;
Fa-Po Chung, MD; Tze-Fan Chao, MD; Gregory Y. H. Lip, MD; Shih-Ann Chen, MD
Abstract
IMPORTANCE Current guidelines recommend the use of non–vitamin K antagonist oral
anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). Data regarding
warfarin sodium use compared with NOAC use in patients with AF with a history of intracranial
hemorrhage (ICH) are limited.
OBJECTIVE To compare the clinical outcomes of warfarin use and NOAC use in patients with AF with
a history of ICH using a nationwide cohort with AF.
DESIGN, SETTING, AND PARTICIPANTS A nationwide cohort study from January 1, 2012, to
December 31, 2016, was performed using data from the Taiwan National Health Insurance Research
Database. The dates of analysis were July 1 to September 1, 2019. The study population comprised
patients with AF with a history of ICH and a CHA2DS2-VASc score (congestive heart failure,
hypertension, age 75 years [doubled], diabetes, prior stroke/transient ischemic attack/
thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery
disease], age 65-74 years, sex category [female]) of at least 1 for men or at least 2 for women who had
received warfarin or NOACs. The clinical outcomes were examined using Cox proportional hazards
regression analyses among the study population before and after propensity score matching.
EXPOSURES Oral anticoagulation with warfarin or NOACs.
MAIN OUTCOMES AND MEASURES The clinical outcomes measured were all-cause mortality,
ischemic stroke, ICH, major bleeding, and adverse events.
RESULTS The study cohort included 4540 patients (mean [SD] age, 76.0 [10.5] years; 2653 men
[58.4%]), with 1047 patients receiving warfarin (mean [SD] age, 75.1 [11.4] years; 571 men [54.5%])
and 3493 patients receiving NOACs (mean [SD] age, 76.3 [10.2] years; 2082 men [59.6%]).
Compared with warfarin use, NOAC use was associated with statistically significantly lower risk of
all-cause mortality (adjusted hazard ratio [aHR], 0.517; 95% CI, 0.457-0.585), ICH (aHR, 0.556; 95%
CI, 0.389-0.796), and major bleeding (aHR, 0.645; 95% CI, 0.525-0.793), whereas the rate of
ischemic stroke was similar in the 2 groups (aHR, 0.879; 95% CI, 0.678-1.141). These results were
generally consistent after propensity score matching among 973 patients in each group.
CONCLUSIONS AND RELEVANCE Among patients with AF with prior ICH, NOAC use was associated
with lower rates of ICH and major bleeding compared with warfarin use, whereas the rate of ischemic
stroke was similar in the 2 groups. Among patients with AF with prior ICH, NOACs could be the
preferred choice for stroke prevention.
JAMA Network Open. 2020;3(6):e206424. doi:10.1001/jamanetworkopen.2020.6424
Key Points
Question Are non–vitamin K antagonist
oral anticoagulants (NOACs) associated
with greater clinical benefit than
warfarin sodium among patients with
atrial fibrillation with a history of
intracranial hemorrhage?
Findings In this cohort study, 4540
patients were identified with prior
intracranial hemorrhage who received
warfarin or NOACs. The use of NOACs
was associated with statistically
significantly lower rates of all-cause
mortality, intracranial hemorrhage, and
major bleeding compared with the use
of warfarin, whereas the rate of ischemic
stroke was similar in the 2 groups.
Meaning Among patients with atrial
fibrillation with prior intracranial
hemorrhage, NOACs could be the
preferred choice for stroke prevention.
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Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia and is an important cause of
ischemic stroke.1 In large randomized studies and meta-analysis,2-7 non–vitamin K antagonist oral
anticoagulants (NOACs) were noninferior to warfarin sodium for comparable risk reduction of
ischemic stroke and less bleeding. Therefore, current guidelines recommend NOAC use in patients
with AF.8-10
Intracranial hemorrhage (ICH) is a serious complication of oral anticoagulant use, and overall
mortality is high once ICH occurs.11 The risk of ischemic stroke is even higher in patients with AF who
survive after ICH compared with those without ICH.12 In observational cohorts, warfarin use was
associated with lower risk of ischemic stroke in patients with AF with prior ICH,13 but there are no
solid trial data on NOAC use in this patient population because patients with prior ICH were excluded
from the relevant randomized trials.3-6 Therefore, it is unknown if the use of NOACs is associated
with lower rates of ischemic stroke and other adverse events in this population. In the present study,
we used a nationwide cohort in Taiwan to compare the clinical outcomes of warfarin use and NOAC
use in patients with AF with a history of ICH.
Methods
This nationwide cohort study used the Taiwan National Health Insurance Research Database (NHIRD)
provided by the Health and Welfare Data Science Center, Ministry of Health and Welfare, Taiwan. The
National Health Insurance system is a mandatory universal health insurance program that offers
comprehensive medical care coverage to all residents of Taiwan. The NHIRD consists of detailed
health care data from more than 23 million enrollees, representing more than 99% of Taiwan’s
population. In this cohort data set, patients’ original identification numbers were encrypted to
protect their privacy, but the encryption was consistent so that a patient’s claims linkage was feasible
within the National Health Insurance database and could be followed continuously. Details about the
NHIRD have been described in previous studies.14-16 The present study was approved by the
institutional review board at Taipei Veterans General Hospital, Taipei, Taiwan. Informed consent was
waived because anonymous data were used. This study followed the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) reporting guideline.
Study Population
From January 1, 2012, to December 31, 2016, a total of 162 124 patients 20 years or older newly
diagnosed as having AF were identified from the NHIRD. The analysis was conducted from July 1 to
September 1, 2019. The diagnosis of AF was identified using the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 427.31, which was registered by
physicians for their patients. The diagnostic accuracy of AF using this definition in the NHIRD has
been validated previously.17 The study population comprised 4540 patients with AF with a history of
ICH and a CHA2DS2-VASc score (congestive heart failure, hypertension, age 75 years [doubled],
diabetes, prior stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior
myocardial infarction or peripheral artery disease], age 65-74 years, sex category [female]) of at least
1 for men or at least 2 for women who had received warfarin (n = 1047) or NOACs (n = 3493 [1430
received dabigatran, 1686 received rivaroxaban, and 377 received apixaban]). The CHA2DS2-VASc
score is based on 10 possible points, with higher scores indicating higher risk. The mean (SD) interval
between the diagnosis of AF and a history of ICH was 5.9 (5.4) years. At the time of prior ICH, among
4540 patients, 4 (0.09%) were receiving NOACs, 494 (10.9%) were receiving warfarin, 1438 (31.7%)
were receiving antiplatelet drugs, and 2697 (59.4%) were receiving no antithrombotic therapy. A
flowchart of patient enrollment and the study design is shown in the eFigure in the Supplement.
JAMA Network Open | Cardiology Warfarin vs NOACs in Patients With AF With a History of Intracranial Hemorrhage
JAMA Network Open. 2020;3(6):e206424. doi:10.1001/jamanetworkopen.2020.6424 (Reprinted) June 1, 2020 2/11
Downloaded From: https://jamanetwork.com/ by a Aalborg University Hospital User  on 09/02/2020
CHA2DS2-VASc Score, HAS-BLED Score, and Clinical End Points
The CHA2DS2-VASc score was calculated for each patient by assigning 1 point each for congestive
heart failure, hypertension, diabetes, vascular disease (prior myocardial infarction or peripheral
artery disease), age between 65 and 74 years, and female sex and 2 points each for prior stroke/
transient ischemic attack (TIA) and age 75 years or older.18 The CHA2DS2-VASc score is recommended
by American and European guidelines to estimate the risk of ischemic stroke in patients with AF and
to guide antithrombotic therapies for stroke prevention.9,10,19 The HAS-BLED (hypertension,
abnormal kidney or liver function, stroke, bleeding history, age 65 years or older, and antiplatelet
drug or alcohol use) score assesses bleeding risk in patients with AF.20 In this study, the HAS-BLED
score ranged from 0 to 8, with higher scores indicating greater risk of bleeding. It was calculated by
assigning 1 point each for hypertension, abnormal kidney or liver function, stroke, bleeding history,
age 65 years or older, and antiplatelet drug or alcohol use.20 Because the international normalized
ratio (INR) for warfarin was not available in the NHIRD, labile INR was excluded from scoring in the
present study, consistent with prior registry studies.21,22 Abnormal kidney or liver function was
defined by ICD-9-CM codes rather than by laboratory data. Herein, the CHA2DS2-VASc and HAS-BLED
scores were used to represent the risk of ischemic stroke and major bleeding, respectively, in the
study population, and the CHA2DS2-VASc score was included as a covariate in the Cox proportional
hazards regression analyses.
Clinical end points were all-cause mortality, ischemic stroke, ICH, major bleeding, and adverse
events. Ischemic stroke was identified using ICD-9-CM codes with concomitant imaging studies,
including computed tomography or magnetic resonance imaging. The accuracy of ischemic stroke
diagnosis in the NHIRD is approximately 94%.23 Another validation study24 demonstrated that the
diagnostic accuracy of ischemic stroke in the NHIRD is high, with a positive predictive value of 88.4%
and a sensitivity of 97.3%. Major bleeding was defined as ICH or bleeding from the gastrointestinal,
genitourinary, or respiratory tract requiring hospitalization.
Statistical Analysis
Continuous variables in each group (warfarin vs NOACs) were expressed as means (SDs), and
categorical variables were expressed as proportions. Differences between continuous values were
assessed using an unpaired 2-tailed t test, and differences between nominal variables were
compared using the χ2 test. The incidence rates of events were calculated by dividing the number of
events across the entire study period by person-years at risk.
Primary Analysis Among the Study Cohort Without Propensity Score Matching
The rates of clinical events with warfarin use vs NOAC use were compared among the unmatched
cohort using multivariable Cox proportional hazards regression analysis adjusted for variables that
were statistically significantly different between the 2 groups, including age, sex, hyperlipidemia,
abnormal kidney function, anemia, use of antiplatelet drugs, and CHA2DS2-VASc score. Subgroup
analysis according to age (65-74 vs 75 years), sex, prior stroke/TIA, heart failure, abnormal kidney
function, and abnormal liver function was also performed with patients receiving warfarin vs those
receiving NOACs in the unmatched cohort.
Propensity Score Matching Analysis (Sensitivity Analysis)
Propensity scores were calculated for the likelihood of receiving warfarin vs NOACs by multivariable
logistic regression analyses conditional on all baseline covariates listed in the Table. Patients in the
warfarin group were then matched 1:1 to patients in the NOAC group on the basis of the closest
propensity score for the use of NOACs within a threshold of ±0.01 using a greedy algorithm. If more
than 1 patient in the NOAC group could be matched to the corresponding patient in the warfarin
group, 1 patient from the NOAC group was randomly selected without repeat sampling. After
propensity score matching, univariate Cox proportional hazards regression analysis was performed
to compare the rates of clinical events with warfarin vs NOACs. Cumulative incidence curves of
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events were plotted using the Kaplan-Meier method among the propensity score–matched cohort
with statistical significance assessed by the log-rank test. Statistical significance was set at 2-tailed
P < .05.
Results
The study cohort included 4540 patients (mean [SD] age, 76.0 [10.5] years; 2653 men [58.4%]),
with 1047 patients receiving warfarin (mean [SD] age, 75.1 [11.4] years; 571 men [54.5%]) and 3493
patients receiving NOACs (mean [SD] age, 76.3 [10.2] years; 2082 men [59.6%]). The mean (SD)
CHA2DS2-VASc score was 5.55 (1.67), with hypertension (4272 [94.1%]) being the most common
comorbidity (Table). Before propensity score matching, patients receiving NOACs were older than
patients receiving warfarin and had higher prevalence of men, prior stroke/TIA, and hyperlipidemia.
Compared with patients receiving NOACs, patients receiving warfarin had higher prevalence of heart
failure, vascular disease, abnormal kidney function, anemia, and use of antiplatelet drugs. The
CHA2DS2-VASc score was higher in patients receiving NOACs vs warfarin (mean [SD], 5.59 [1.63] vs
5.43 [1.81]; P = .009), whereas there was no statistically significant difference in HAS-BLED scores in
patients receiving NOACs vs warfarin (mean [SD], 4.30 [1.02] vs 4.31 [1.15]; P = .81). After propensity
Table. Baseline Characteristics of the Whole Population and the Matched Population
Variable
Whole population Matched population
All (N = 4540) Warfarin (n = 1047) NOACs (n = 3493) P value Warfarin (n = 973) NOACs (n = 973) P value
Age, mean (SD), y 76.0 (10.5) 75.1 (11.4) 76.3 (10.2) .002 75.5 (11.1) 75.7 (10.7) .65
Age, No. (%), y
65-74 1154 (25.4) 250 (23.9) 904 (25.9) .19 233 (23.9) 246 (25.3) .49
≥75 2743 (60.4) 595 (56.8) 2148 (61.5) .007 566 (58.2) 587 (60.3) .33
Male, No. (%) 2653 (58.4) 571 (54.5) 2082 (59.6) .004 543 (55.8) 502 (51.6) .06
Comorbidities, No. (%)
Hypertension 4272 (94.1) 981 (93.7) 3291 (94.2) .53 911 (93.6) 911 (93.6) >.99
Diabetes 2277 (50.2) 522 (49.9) 1755 (50.2) .83 478 (49.1) 509 (52.3) .16
Prior stroke/TIA 3393 (74.7) 705 (67.3) 2688 (77.0) <.001 673 (69.2) 678 (69.7) .81
Heart failure 2495 (55.0) 631 (60.3) 1864 (53.4) <.001 573 (58.9) 584 (60.0) .61
Vascular disease 843 (18.6) 220 (21.0) 623 (17.8) .03 192 (19.7) 191 (19.6) .96
Myocardial infarction 472 (10.4) 140 (13.4) 332 (9.5) <.001 105 (10.8) 107 (11.0) .90
Peripheral artery disease 422 (9.3) 97 (9.3) 325 (9.3) .97 93 (9.6) 92 (9.5) .94
COPD 2399 (52.8) 544 (52.0) 1855 (53.1) .51 514 (52.8) 534 (54.9) .36
Hyperlipidemia 2633 (58.0) 556 (53.1) 2077 (59.5) <.001 520 (53.4) 550 (56.5) .17
Autoimmune diseases 446 (9.8) 100 (9.6) 346 (9.9) .74 92 (9.5) 92 (9.5) >.99
Cancer 744 (16.4) 161 (15.4) 583 (16.7) .31 151 (15.5) 165 (17.0) .39
Abnormal kidney function 1135 (25.0) 338 (32.3) 797 (22.8) <.001 280 (28.8) 294 (30.2) .487
Abnormal liver function 1581 (34.8) 342 (32.7) 1239 (35.5) .091 327 (33.6) 350 (36.0) .27
Anemia 947 (20.9) 301 (28.7) 646 (18.5) <.001 248 (25.5) 246 (25.3) .92
History of bleeding 4540 (100) 1047 (100) 3493 (100) NA 973 (100) 973 (100) NA
Alcohol excess/abuse 177 (3.9) 41 (3.9) 136 (3.9) .97 39 (4.0) 35 (3.6) .64
Use of antiplatelet drugs, No. (%) 510 (11.2) 197 (18.8) 313 (9.0) <.001 150 (15.4) 150 (15.4) >.99
Use of NSAIDs, No. (%) 156 (3.4) 40 (3.8) 116 (3.3) .44 38 (3.9) 40 (4.1) .82
CHA2DS2-VASc score, mean (SD) 5.55 (1.67) 5.43 (1.81) 5.59 (1.63) .009 5.44 (1.79) 4.59 (1.71) .06
HAS-BLED score, mean (SD) 4.31 (1.05) 4.31 (1.15) 4.30 (1.02) .81 4.29 (1.15) 4.35 (1.13) .25
Propensity score, mean (SD) NA NA NA NA 0.74 (0.10) 0.74 (0.10) .86
Abbreviations: CHA2DS2-VASc, congestive heart failure, hypertension, age at least 75
years (doubled), diabetes, prior stroke/TIA/thromboembolism (doubled), vascular
disease (prior myocardial infarction or peripheral artery disease), age 65 to 74 years, sex
category (female); COPD, chronic obstructive pulmonary disease; HAS-BLED,
hypertension, abnormal kidney or liver function, stroke, bleeding history, age 65 years or
older, and antiplatelet drug or alcohol use; NA, not applicable; NOACs, non–vitamin K
antagonist oral anticoagulants; NSAID, nonsteroidal anti-inflammatory drug; TIA,
transient ischemic attack.
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score matching, 973 matched patients whose baseline characteristics did not differ significantly
remained in each group (Table).
Risk of Clinical End Points in the Original Cohort Before Propensity Score Matching
The annual risk of clinical end points and comparison between warfarin and NOACs are shown in
Figure 1. All-cause mortality occurred in 421 patients receiving warfarin and in 682 patients receiving
NOACs, with an annual incidence of 21.70% (95% CI, 19.63%-23.77%) and 11.95% (95% CI,
11.05%-12.85%), respectively. In addition, 78 patients receiving warfarin and 226 patients receiving
NOACs had ischemic stroke, with an annual incidence of 4.25% (95% CI, 3.31%-5.19%) and 4.20%
(95% CI, 3.65%-4.75%), respectively. Multivariable Cox proportional hazards regression analysis
showed that NOAC use was associated with lower risk of all-cause mortality (adjusted hazard ratio
[aHR], 0.517; 95% CI, 0.457-0.585; P < .001) and similar risk of ischemic stroke (aHR, 0.879; 95% CI,
0.678-1.141; P = .33) compared with warfarin use.
Regarding safety end points, 50 patients receiving warfarin and 83 patients receiving NOACs
had ICH, with an annual incidence of 2.65% (95% CI, 1.92%-3.38%) and 1.48% (95% CI,
1.16%-1.80%), respectively (Figure 1). Moreover, 139 patients receiving warfarin and 282 patients
receiving NOACs experienced major bleeding, with an annual incidence of 7.84% (95% CI,
6.54%-9.14%) and 5.33% (95% CI, 4.71%-5.95%), respectively. Multivariable Cox proportional
hazards regression analysis showed that NOAC use was associated with lower risk of ICH (aHR,
0.556; 95% CI, 0.389-0.796; P = .001) and major bleeding (aHR, 0.645; 95% CI, 0.525-0.793;
P < .001) compared with warfarin use. Overall, NOAC use was associated with decreased risk of
adverse events (aHR, 0.596; 95% CI, 0.534-0.665; P < .001) compared with warfarin use.
Risk of Clinical End Points in the Cohort After Propensity Score Matching
The annual risk of clinical end points and comparison between warfarin and NOACs after propensity
score matching are shown in Figure 1. The principal findings were generally consistent with those of
multivariable Cox proportional hazards regression analysis performed among the cohort before
propensity score matching. Compared with warfarin use, NOAC use was associated with statistically
significantly lower risk of all-cause mortality (HR, 0.539; 95% CI, 0.453-0.642; P < .001), ICH (HR,
0.614; 95% CI, 0.379-0.995; P = .048), and major bleeding (HR, 0.752; 95% CI, 0.573-0.986;
P = .04), whereas the risk of ischemic stroke was similar (HR, 0.985; 95% CI, 0.713-1.361; P = .93)
Figure 1. Clinical End Points of Non–vitamin K Antagonist Oral Anticoagulant (NOAC) Use Compared
With Warfarin Use Before and After Propensity Score Matching
P valueFavors
NOACs
Favors
warfarin
210.2
HR (95% CI)
210.2
aHR (95% CI)
No. of events (% per year)
Warfarin NOACs
Before
matching
aHR
(95% CI)
P valueFavors
NOACs
Favors
warfarin
No. of events (% per year)
Warfarin NOACs
After
matching
HR
(95% CI)
<.001All-cause mortality
.33Ischemic stroke
.001 ICH
<.001Major bleeding
<.001Adverse events
<.001All-cause mortality
.93Ischemic stroke
.048 ICH
.04Major bleeding
<.001Adverse events
421 (21.70) 682 (11.95) 0.517 (0.457-0.585)
78 (4.25) 226 (4.20) 0.879 (0.678-1.141)
50 (2.65) 83 (1.48) 0.556 (0.389-0.796)
139 (7.84) 282 (5.33) 0.645 (0.525-0.793)
505 (30.03) 978 (19.50) 0.596 (0.534-0.665)
389 (21.28) 187 (11.80) 0.539 (0.453-0.642)
76 (4.41) 72 (4.87) 0.985 (0.713-1.361)
46 (2.59) 26 (1.68) 0.614 (0.379-0.995)
128 (7.67) 89 (6.13) 0.752 (0.573-0.986)
471 (29.86) 281 (20.73) 0.657 (0.567-0.762)
Before matching, multivariable Cox proportional
hazards regression analysis showed that NOAC use
was associated with lower rates of all-cause mortality,
ICH, major bleeding, and adverse events and a similar
rate of ischemic stroke compared with warfarin sodium
use. After matching, the principal findings were
generally consistent with those before matching. aHR
indicates adjusted hazard ratio; HR, hazard ratio; and
ICH, intracranial hemorrhage.
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(Figure 1). Cumulative incidence curves of clinical end points among the propensity score–matched
cohort are shown in Figure 2.
Subgroup Analysis
Figure 3 compares adverse events in different subgroups for warfarin vs NOACs. The use of NOACs
was consistently associated with a lower rate of adverse events (interaction P > .05 in all subgroups
except for age), which was more evident among patients 75 years or older (aHR, 0.564; 95% CI,
0.496-0.641) than those younger than 75 years (aHR, 0.700; 95% CI, 0.571-0.858)
(interaction P = .02).
Discussion
This nationwide cohort study compared the rates of all-cause mortality, ischemic stroke, ICH, major
bleeding, and adverse events associated with warfarin use vs NOAC use in patients with AF with a
history of ICH, with 2 main findings. First, compared with warfarin use, NOAC use was associated with
statistically significantly lower risk of all-cause mortality, ICH, and major bleeding, whereas the rate
of ischemic stroke was similar in the 2 groups. Second, in subgroup analysis, NOAC use was
consistently associated with a lower rate of adverse events than warfarin use.
Figure 2. Cumulative Incidence Curves of Clinical End Points Among the Propensity Score–Matched Cohort Using the Kaplan-Meier Method
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Cumulative incidence curves for all-cause mortality (A), ICH (C), and major bleeding (D) were lower for non–vitamin K antagonist oral anticoagulant (NOAC) use compared with
warfarin sodium use. Cumulative incidence curves for ischemic stroke were similar for warfarin use and NOAC use (B). ICH indicates intracranial hemorrhage.
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The use of oral anticoagulants for stroke prevention in patients with AF should balance the risk
of stroke if left untreated and increased bleeding risk if anticoagulated.25 Bleeding risk is a main
reason why physicians withhold oral anticoagulant therapy in patients with AF. In the Outcomes
Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), which studied 10 130
patients with AF, 13.1% had contraindications to oral anticoagulation documented by a health care
professional, with a prior bleeding event reported in 27.7% of these patients, high bleeding risk in
18.0%, and prior ICH in 5.0%.26 Improved safety of NOACs compared with warfarin, especially a 52%
lower risk of ICH,2 has changed the landscape of stroke prevention in AF. Data from 2 global registry
studies demonstrated that overall oral anticoagulant use statistically significantly increased from
57.4% in 2010-2011 to 71.1% in 2014-2015 in the Global Anticoagulant Registry in the FIELD–Atrial
Fibrillation (GARFIELD-AF)27 and from 52.4% in 2008 to 60.7% in 2014 in the National
Cardiovascular Data Registry PINNACLE registry.28 These statistically significant increased rates of
oral anticoagulant use were largely attributable to greater prescription of NOACs (from 4.2% to 37%
during the study period in GARFIELD-AF and from 0% to 25.8% during the study period in the
National Cardiovascular Data Registry PINNACLE registry), although regional differences are
evident.27-29 In Asia, the rates of appropriate prescription of oral anticoagulants have also statistically
significantly increased, with NOACs commonly prescribed since they became available.30,31 In
Taiwan, oral anticoagulant prescription rates increased from 13.6% in 2008 to 35.6% in 2015, and
NOACs accounted for 73% of overall oral anticoagulants prescribed for patients with incident AF in a
2018 study.31
Despite increasing prescription of NOACs worldwide, some high-risk populations were excluded
from the pivotal trials3-6 of warfarin vs NOACs (eg, patients with AF with prior ICH). In our study, we
compared clinical event rates associated with warfarin use and NOAC use in this high-risk population
with a mean CHA2DS2-VASc score of 5.55 and a mean HAS-BLED score of 4.31. In a previous report,
the annual ICH risk in Taiwan was 1.41% for patients with AF treated with warfarin and 0.70% to
0.74% for patients with AF treated with NOACs.32 In the present study, the annual risk of recurrent
ICH for patients with AF with a history of ICH was 2.65% for warfarin and 1.48% for NOACs. These
Figure 3. Risk of Adverse Events Associated With Non–vitamin K Antagonist Oral Anticoagulant (NOAC) Use Compared With Warfarin Use in Different Subgroups
P valueFavors
NOACs
Favors
warfarin
210.2
aHR (95% CI)
No. of events (% per year)
Warfarin NOACs
Other adverse
events
Age, y
aHR
(95% CI)
No. of
patients
.02
65-74
≥75
Sex .42
Female
Male
Prior stroke/TIA .84
Yes
No
Abnormal kidney function .06
Yes
No
Abnormal liver function .78
Yes
No
152 (17.81) 272 (13.14) 0.700 (0.571-0.858)
353 (42.65) 706 (23.97) 0.564 (0.496-0.641)
245 (35.44) 408 (20.42) 0.525 (0.447-0.617)
260 (26.26) 570 (18.90) 0.660 (0.569-0.766)
368 (32.06) 799 (20.09) 0.604 (0.533-0.685)
188 (42.40) 241 (23.65) 0.654 (0.572-0.747)
317 (25.61) 737 (18.45) 0.522 (0.428-0.637)
173 (33.93) 363 (21.16) 0.597 (0.522-0.684)
332 (28.34) 615 (18.64) 0.593 (0.493-0.713)
137 (25.68)
1797
2743
1887
2653
3393
1135
3405
1581
2959
1147 179 (17.25) 0.582 (0.463-0.732)
Heart failure .47
Yes
No
325 (34.61) 599 (23.20) 0.617 (0.538-0.708)
180 (24.25)
2495
2045 379 (15.58) 0.575 (0.480-0.689)
Subgroup analysis according to age, sex, prior stroke/TIA, heart failure, abnormal kidney
function, and abnormal liver function was performed. Compared with warfarin sodium
use, NOAC use was associated with a lower rate of adverse events in all subgroups, which
was more evident among patients 75 years or older than those aged 65 to 74 years. aHR
indicates adjusted hazard ratio; and TIA, transient ischemic attack.
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observations show that patients with AF with prior ICH are at high risk for recurrent ICH despite the
type of oral anticoagulant received. However, our results demonstrate that NOAC use is still
associated with a statistically significantly lower rate of ICH (aHR, 0.56) and major bleeding (aHR,
0.65) compared with warfarin use and thus should be a more favorable choice for stroke prevention
in this population. The 44% lower rate of ICH we observed for NOAC use compared with warfarin
use is close to that observed in the pooled analysis of the 4 NOAC trials3-6 (52%) that only enrolled
patients with AF without a history of ICH. Therefore, the present study provides important data that
were lacking in the randomized trials3-6 and should be complementary to the current literature on
stroke prevention using NOACs.
In addition to the lower rates of ICH and major bleeding associated with NOAC use, we observed
a lower rate of all-cause mortality with NOACs compared with warfarin, which was not demonstrated
in 3 of the NOAC trials,4-6 with the exception being apixaban use in the Apixaban for Reduction in
Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study.2 In contrast to the
randomized trials, observational studies32-34 showed a statistically significantly lower mortality rate
with NOAC use compared with warfarin use. However, a possible explanation for this difference is
that some deaths in observational cohorts may be from unrecorded fatal strokes or ICH because not
all outcomes are adjudicated and postmortem examinations are not mandated. Therefore, lower
mortality with NOAC use may in part be associated with lower risk of stroke and ICH. However, some
unmeasured confounders associated with warfarin or NOAC prescription that were also associated
with mortality were likely present and may have confounded the analyses.
Limitations
Our study has some limitations. First, this nationwide cohort study was based on the Taiwan NHIRD
and may be limited by coding errors. However, diagnoses of AF, stroke, and other comorbidities in
this data set are well validated.17,23,24,35 Second, detailed information on prior ICH events was not
available, such as location on imaging, severity, and functional disabilities, all of which might
influence the choice of oral anticoagulants. Third, data were lacking on the INR and on time in the
therapeutic range of warfarin. Fourth, although we tried to adjust for baseline differences between
the warfarin and NOAC groups using multivariable Cox proportional hazards regression analyses and
propensity score matching, some selection bias might have remained that could have altered the
outcomes.
Conclusions
Among patients with AF with a history of ICH, NOAC use was associated with lower rates of ICH and
major bleeding compared with warfarin use, whereas the rate of ischemic stroke was similar in the 2
groups. In this high-risk population with AF, NOACs could be the preferred choice for stroke
prevention.
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